NORDITROPIN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NORDITROPIN (NORDITROPIN).

How it works

Human growth hormone (hGH) binds to growth hormone receptors on target cells, activating JAK2/STAT5 signaling pathway, which stimulates insulin-like growth factor 1 (IGF-1) production in the liver and other tissues, promoting linear growth and anabolic effects.

What the body does with it

Metabolism	Hepatic metabolism; primarily metabolized in the liver via proteolysis; undergoes receptor-mediated degradation.
Excretion	Renal: >90% via glomerular filtration and tubular reabsorption with metabolism in proximal tubules; unchanged drug and metabolites.
Half-life	IV: 0.5-1.5 hours (initial), 3-5 hours (terminal); SC: 2-4 hours (mean 3.5 hours). Clinical context: Short half-life necessitates daily dosing; terminal half-life reflects slow absorption from SC depot.
Protein binding	~80% bound to growth hormone binding protein (GHBP), a soluble fragment of the GH receptor.
Volume of Distribution	0.5-1.0 L/kg; primarily distributes to extracellular fluid and highly perfused tissues (liver, kidneys). Low Vd consistent with a large protein (22 kDa) not crossing cell membranes.
Bioavailability	SC: ~80-90% (relative to IV). Intramuscular: ~70-80%.
Onset of Action	SC: IGF-1 levels increase within 3-6 hours; clinical effects (growth) evident after weeks to months of therapy.
Duration of Action	SC: Serum GH elevated for 12-18 hours; clinical growth effects persist with daily dosing. Note: Duration of metabolic effects (lipolysis, protein synthesis) extends beyond GH clearance.

Classification & Brands

Dosing & administration

0.2-0.3 mg/kg/week subcutaneously divided into 6-7 daily doses; maximum 0.7 mg/kg/week

Dosage form	INJECTABLE
Renal impairment	Contraindicated in patients with end-stage renal disease and active neoplasia; GFR <30 mL/min: use with caution, consider dose reduction by 50%
Liver impairment	No specific dose adjustment guidelines for Child-Pugh classification; use with caution in severe hepatic impairment
Pediatric use	Growth hormone deficiency: 0.16-0.33 mg/kg/week subcutaneously divided into 6-7 daily doses; Turner syndrome: 0.33-0.47 mg/kg/week; chronic renal insufficiency: 0.35 mg/kg/week
Geriatric use	Start at low end of dosing range (0.1-0.2 mg/kg/week) due to increased risk of adverse effects; monitor IGF-1 levels and adjust dose to maintain in age-adjusted normal range

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NORDITROPIN (NORDITROPIN).

Breastfeeding	Endogenous growth hormone is present in human milk. Exogenous somatropin is likely absorbed and degraded in the infant GI tract. No specific M/P ratio available. Caution in breastfeeding infants due to potential for growth effects, but no adverse events reported.
Teratogenic Risk	No evidence of teratogenicity in animal studies. Limited human data; growth hormone does not cross the placenta in significant amounts. Therefore, no known fetal risk when used in the first trimester. Use in second and third trimesters may be associated with increased risk of gestational diabetes, but no direct teratogenic effects have been reported.

Warnings & precautions

■ FDA Black Box Warning

Increased risk of mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma, or those with acute respiratory failure.

Side Effect Profile

Serious Effects

Absolute Contraindications

Acute critical illness; active malignancy; diabetic retinopathy; children with closed epiphyses; hypersensitivity to growth hormone or excipients; Prader-Willi syndrome patients with severe obesity or severe respiratory impairment.

Clinical Precautions

Precautions

Risk of second malignancy in patients treated for childhood cancer; increased risk of leukemia; intracranial hypertension; severe allergic reactions; fluid retention; glucose intolerance; hypothyroidism; slipped capital femoral epiphysis; pancreatitis; lipoatrophy at injection site.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NORDITROPIN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NORDITROPIN (NORDITROPIN).

How it works

What the body does with it

Metabolism	Hepatic metabolism; primarily metabolized in the liver via proteolysis; undergoes receptor-mediated degradation.
Excretion	Renal: >90% via glomerular filtration and tubular reabsorption with metabolism in proximal tubules; unchanged drug and metabolites.
Half-life	IV: 0.5-1.5 hours (initial), 3-5 hours (terminal); SC: 2-4 hours (mean 3.5 hours). Clinical context: Short half-life necessitates daily dosing; terminal half-life reflects slow absorption from SC depot.
Protein binding	~80% bound to growth hormone binding protein (GHBP), a soluble fragment of the GH receptor.
Volume of Distribution	0.5-1.0 L/kg; primarily distributes to extracellular fluid and highly perfused tissues (liver, kidneys). Low Vd consistent with a large protein (22 kDa) not crossing cell membranes.
Bioavailability	SC: ~80-90% (relative to IV). Intramuscular: ~70-80%.
Onset of Action	SC: IGF-1 levels increase within 3-6 hours; clinical effects (growth) evident after weeks to months of therapy.
Duration of Action	SC: Serum GH elevated for 12-18 hours; clinical growth effects persist with daily dosing. Note: Duration of metabolic effects (lipolysis, protein synthesis) extends beyond GH clearance.

Classification & Brands

Dosing & administration

0.2-0.3 mg/kg/week subcutaneously divided into 6-7 daily doses; maximum 0.7 mg/kg/week

Dosage form	INJECTABLE
Renal impairment	Contraindicated in patients with end-stage renal disease and active neoplasia; GFR <30 mL/min: use with caution, consider dose reduction by 50%
Liver impairment	No specific dose adjustment guidelines for Child-Pugh classification; use with caution in severe hepatic impairment
Pediatric use	Growth hormone deficiency: 0.16-0.33 mg/kg/week subcutaneously divided into 6-7 daily doses; Turner syndrome: 0.33-0.47 mg/kg/week; chronic renal insufficiency: 0.35 mg/kg/week
Geriatric use	Start at low end of dosing range (0.1-0.2 mg/kg/week) due to increased risk of adverse effects; monitor IGF-1 levels and adjust dose to maintain in age-adjusted normal range

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NORDITROPIN (NORDITROPIN).

Breastfeeding	Endogenous growth hormone is present in human milk. Exogenous somatropin is likely absorbed and degraded in the infant GI tract. No specific M/P ratio available. Caution in breastfeeding infants due to potential for growth effects, but no adverse events reported.
Teratogenic Risk	No evidence of teratogenicity in animal studies. Limited human data; growth hormone does not cross the placenta in significant amounts. Therefore, no known fetal risk when used in the first trimester. Use in second and third trimesters may be associated with increased risk of gestational diabetes, but no direct teratogenic effects have been reported.